CClinicalTrials.gg
CompletedNCT02867150Updated Jun 23, 2017Results posted

A Retrospective Analysis of the Effects of Red Light Therapy on Body Contouring

An interventional study of Ward Photonics Photonica Professional in Obesity, sponsored by Ward Photonics LLC. Completed. Open to participants aged 18 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-23.

Sponsored by Ward Photonics LLC · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
58
Allocation
Not applicable
Ages
18 Years to 74 Years
Sex
All
01

Study summary

The purpose of this study is to determine whether red light therapy using LED 635nm red light for body contouring of the waist, hips and thighs is as effective as red light therapy using Laser 635nm red light.

Read the detailed description

Red light laser therapy using 635nm red light laser technology has previously been shown to cause lipolysis in subcutaneous fat as a non-surgical method to promote weight loss and body contouring. This study hypothesizes that red LED light therapy using 635nm red light LED (light emitting diode) technology produces similar results to the laser device (red LASER 635nm) when performed using a specified treatment protocol.

Furthermore, it is hypothesized that the UltraSlim Cold Light therapy program achieves the results after a single 32-minute treatment. The predicate 635nm laser device (Zerona by Erchonia) achieves its results after six treatments combined with a diet and exercise regimen.

UltraSlim Cold Light® is a patented process using the Photonica Professional device for fat removal using LED red light therapy. This multi-site study reviews results from 58 randomly selected patients after a single treatment using the Photonica Professional device (i.e. UltraSlim Cold Light®).

02

Conditions studied

  • Obesity
03

In context

Lead sponsor

Ward Photonics LLC is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • 18 years or older.
  • Male or female.
  • Generally good health.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy.
  • Active cancer within the past year.
  • Diminished ability to void waste (liver or kidneys).
  • Photosensitive condition or medication.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Active Device

    Active Device: Ward Photonics Photonica Professional Red light therapy system Intervention: Device: Ward Photonics Photonica Professional

    Device: Ward Photonics Photonica Professional

Interventions

  • DeviceWard Photonics Photonica Professional

    Active Device: Ward Photonics, Photonica Professional Red light therapy system UltraSlim Cold Light® is the name of a patented treatment regimen using the Photonica Professional device for fat removal using LED red light therapy.

06

What researchers measure

Primary outcomes

  1. Fat Reduction in Treatment Zone as Measured in Inches Lost

    Circumferential measurement of thighs, hips and waist before and after treatment.

    Time frame: Single 32-minute treatment session

07

Results

Posted Jun 23, 2017

Participant flow

Participant flow — Overall Study
MilestoneActive Device
Started58
Completed58
Not completed0

Outcome measures

PrimaryFat Reduction in Treatment Zone as Measured in Inches Lost

Circumferential measurement of thighs, hips and waist before and after treatment.

Time frame:
Single 32-minute treatment session
Reported as:
Mean · inch
Fat Reduction in Treatment Zone as Measured in Inches Lost
inchActive Device
Fat Reduction in Treatment Zone as Measured in Inches Lost3.5 (1.625 to 10)

Adverse events

Collected over 6 MONTHS. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active Device—0/58 (0%)0/58 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Active Device
<=18 years1
Between 18 and 65 years54
>=65 years3
Age, Continuous
Age, Continuous(Years)Active Device
Mean43.3 (18 to 74)
Sex: Female, Male
Sex: Female, Male(Participants)Active Device
Female46
Male12
Region of Enrollment
Region of Enrollment(participants)Active Device
United States58
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: No — No current plan to share data.

No publications or documents are linked to this record.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02867150
Lead sponsor
Ward Photonics LLC
Responsible party
Sponsor
First posted
Aug 15, 2016
Start date
Oct 2015
Primary completion
Oct 2015
Completion
Oct 2015
Results posted
Jun 23, 2017
Last update
Jun 23, 2017

Study contacts

Terry J Ward, M.H.A.
principal investigator · Managing Director

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion